including Sage Therapeutics/Biogen's GABA A receptor modulator zuranolone – heading for an FDA decision next year – and Axsome Therapeutics' oral NMDA receptor antagonist Auvelity ...
Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback